Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Meyers Primary Care Institute, University of Massachusetts Medical School, Worcester, MA, USA.
Clin Ther. 2019 Dec;41(12):2467-2476. doi: 10.1016/j.clinthera.2019.08.016. Epub 2019 Sep 25.
Medication use in pregnancy is common, but information about the safety of most medications in pregnant women or their infants is limited. In the absence of data from randomized clinical trials to guide decisions made by regulators, clinicians, and patients, we often have to rely on well-designed observational studies to generate valid evidence about the benefits and risks of medications in pregnancy. Spontaneous reporting, primary case-control and cohort studies, pregnancy exposure registries, and electronic health data have been used extensively for studying medication safety in pregnancy. This article discusses these data sources, their strengths and limitations, and possible strategies and approaches to mitigating limitations when planning studies or interpreting findings from the literature. Strategies discussed include combining data sources across institutional or national borders, developing and using more sophisticated study designs, and taking advantage of existing analytic methods for more complex data structures, such as time-varying exposure or unmeasured confounding. Finally, we make recommendations for study designs that aid in better risk-related communication.
孕期用药较为常见,但关于大多数药物在孕妇及其婴儿中的安全性信息有限。由于缺乏随机临床试验数据来指导监管机构、临床医生和患者做出决策,我们通常不得不依赖精心设计的观察性研究来产生关于药物在孕期中获益和风险的有效证据。自发报告、原始病例对照和队列研究、妊娠暴露登记处和电子健康数据已广泛用于研究孕期用药安全性。本文讨论了这些数据源,以及它们的优缺点,以及在规划研究或解释文献结果时减轻局限性的可能策略和方法。讨论的策略包括整合跨越机构或国家边界的数据源,开发和使用更复杂的研究设计,以及利用现有的分析方法来处理更复杂的数据结构,例如时变暴露或未测量的混杂因素。最后,我们提出了有助于更好地进行风险相关沟通的研究设计建议。